Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. In the United States, it is also approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and a left ventricular ejection fraction (LVEF) of 40% or greater. Finerenone is a non-steroidal mineralocorticoid receptor antagonist. It is taken orally (swallowed by mouth).
Read the full article on WikipediaChronic kidney disease with Type 2 diabetes Clinical criteria: Patient must have a diagnosis of chronic kidney disease, defined as abnormalities of at least one of: (i) kidney structure, (ii) kidney function, present for at least 3 months, prior to initiating treatment with this drug, AND Patient must not have known significant non-diabetic renal disease, prior to initiating treatment with this drug, AND Patient must have an estimated glomerular filtration rate of 25 mL/min/1.73 m2 or greater, prior to initiating treatment with this drug, AND Patient must have a urinary albumin-to-creatinine ratio of 200 mg/g (22.6 mg/mmol) or greater, prior to initiating treatment with this drug, AND Patient must discontinue treatment with this drug prior to initiating renal replacement therapy, defined as dialysis or kidney transplant, AND Patient must be stabilised, for at least 4 weeks, on either: (i) an ACE inhibitor or (ii) an angiotensin II receptor antagonist, unless medically contraindicated, prior to initiation of combination therapy with this drug, AND The treatment must be in combination with an SGLT2i unless medically contraindicated or intolerant, AND Patient must not be receiving treatment with another selective nonsteroidal mineralocorticoid receptor antagonist, a renin inhibitor or a potassium-sparing diuretic, AND Patient must not have established heart failure with reduced ejection fraction with an indication for treatment with a mineralocorticoid receptor antagonist.
Working under the parallel aged-care framework? Aged-care equivalent →